The Role of p53-inducible Sesn1 and Sesn2 genes in lung carcinogenesis
The Role of p53-inducible Sesn1 and Sesn2 genes in lung carcinogenesis
批准号:
8997468
负责人:
Steven R. Grossman
金额:
$31.64万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-02-01 至 2018-01-31
关键词:
AddressAdenocarcinomaAffectAutophagocytosisCancer EtiologyCancer ModelCell Cycle ArrestCell DeathCell ProliferationCell Proliferation RegulationCell SurvivalCellsCessation of lifeDNA DamageDepressed moodDevelopmentDiagnosisDiagnosticDiseaseEpithelial Cell ProliferationFRAP1 geneGene FamilyGenesGeneticGoalsHealthHumanK-ras mouse modelKRAS2 geneKnockout MiceKnowledgeLinkLungMalignant neoplasm of lungMediatingMesenchymalMetabolismMissionModelingMusMutagenesisMutationNeoplasm MetastasisNon-Small-Cell Lung CarcinomaOutcomeOxidative StressPathway interactionsPatientsPharmaceutical PreparationsPhosphotransferasesPropertyProtein p53Proto-OncogenesPublic HealthRadiation therapyReactive Oxygen SpeciesRegulationResearchRoleSTK11 geneSignal PathwayStagingStressStructure of parenchyma of lungSuppressor GenesSurvival RateTP53 geneTranscriptional RegulationTumor AngiogenesisTumor SuppressionTumor Suppressor GenesTumor Suppressor ProteinsWorkXenograft procedureadenomaangiogenesisanticancer treatmentbasecancer cellcancer initiationcancer therapycarcinogenesiscell growthdesignimprovedirradiationlung carcinogenesismTOR Signaling PathwaymTOR inhibitionmitochondrial dysfunctionmortalitymouse modelmutantnovelnovel strategiesoverexpressionoxidative damageresponsetraittumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Around a million people are diagnosed with non-small cell lung cancer (NSCLC) worldwide each year and 85% of them will die during next 5 years. In spite of considerable efforts to improve the diagnostics and efficiency of treatment, the changes in mortality rate for the last couple decades is less than 2%. New effective approaches for anti-cancer therapy are hindered by the lack of knowledge of the mechanisms of lung carcinogenesis and a predictive strategy for efficient treatment. Among the genes dysregulated in NSCLC mutations in p53 and LKB1 are major traits, and their critical effect on lung carcinogenesis is supported by many mouse models. P53 suppresses carcinogenesis through transcriptional regulation of a number of genes, although the critical targets involved in tumor suppression are unknown. The LKB1 kinase phosphorylates and activates AMPK leading to inhibition of mTOR kinase, critical regulator of cell growth, proliferation and metabolism, which i activated in many lung cancers. Strikingly, similar to LKB1 p53 inhibits mTOR through activation of AMPK, although the inter-relation between p53- and LKB1-regulated signaling pathways is not well characterized. Recently we described a novel Sestrin (Sesn) gene family of stress-responsive genes in which expression is regulated in a p53-dependent manner. Sesns inhibit mTOR through AMPK regulation causing inhibition of cell growth and proliferation, activation of autophagy and protection against oxidative damage. Sesn1 and Sesn2 are downregulated in most human lung cancers and this leads to dysregulation of tumor growth and angiogenesis, so the Sesns are potential tumor suppressors and effectors of p53. The objective of the proposed work is to establish the importance of Sesn1 and Sesn2 in suppression of lung carcinogenesis and the outcome of anticancer treatment. To accomplish that we set up the following specific aims: Aim 1: To determine tumor suppressor properties of Sesn1 and Sesn2. We will apply of mouse model of K-ras-induced lung carcinogenesis and study whether inactivation or overexpression of Sesns modulate lung carcinogenesis. We will address the potential mechanisms, which involve regulation of cell proliferation and cell death, oxidative stress, autophagy and metabolism. Aim 2: To study the impact of the AMPK-mTOR pathway in regulation of carcinogenesis by Sesn1/2. We will analyze the role of Sesn1/2 in regulation of the AMPK-mTOR pathway in lung tissue and cancers and study whether the modulation of this pathway affects tumor-suppression function of Sesns. Aim 3: To understand the role of Sesn1/2 in anticancer treatment. We will treat Sesn1/2-deficient and proficient tumors and cancer cells with irradiation and DNA-damaging drugs and determine the impact of Sesn1/2 in tumor growth, cell viability and proliferation. The accomplishment of these goals let us to understand the mechanisms of tumor suppression in lung and design the more advanced approaches to diagnose and treat lung cancers decreasing the enormous death toll.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of p53-inducible Sesn1 and Sesn2 genes in lung carcinogenesis
-
批准号:9198533
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2013
-
负责人:Steven R. Grossman
-
依托单位:
Targeting the ARF/CtBP Axis in Pancreatic Cancer
-
批准号:7942815
-
项目类别:
-
资助金额:$8.23万
-
财政年份:2009
-
负责人:Steven R. Grossman
-
依托单位:
Targeting the ARF/CtBP Axis in Pancreatic Cancer
-
批准号:7774126
-
项目类别:
-
资助金额:$8.2万
-
财政年份:2009
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300 and hHR23 proteins in p53 regulation
-
批准号:7046171
-
项目类别:
-
资助金额:$28.65万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300 and hHR23 proteins in p53 regulation
-
批准号:7215281
-
项目类别:
-
资助金额:$27.82万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300/CBP and hHR23 Proteins in p53 Regulation
-
批准号:8444644
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300/CBP and hHR23 Proteins in p53 Regulation
-
批准号:8066637
-
项目类别:
-
资助金额:$21.9万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
p300 and hHR23 proteins in p53 regulation
-
批准号:6770901
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300/CBP and hHR23 Proteins in p53 Regulation
-
批准号:8287740
-
项目类别:
-
资助金额:$6.85万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300/CBP and hHR23 Proteins in p53 Regulation
-
批准号:8606421
-
项目类别:
-
资助金额:$25.35万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300 and hHR23 proteins in p53 regulation
-
批准号:7367085
-
项目类别:
-
资助金额:$27.82万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300 and hHR23 proteins in p53 regulation
-
批准号:6880147
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300/CBP and hHR23 Proteins in p53 Regulation
-
批准号:7892214
-
项目类别:
-
资助金额:$29.62万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
Role of p300/CBP and hHR23 Proteins in p53 Regulation
-
批准号:8210879
-
项目类别:
-
资助金额:$25.45万
-
财政年份:2004
-
负责人:Steven R. Grossman
-
依托单位:
ROLE OF MDM2, P300, P19ARF IN P53 UBIQUITINATION
-
批准号:6233513
-
项目类别:
-
资助金额:$13.58万
-
财政年份:2001
-
负责人:Steven R. Grossman
-
依托单位:
ROLE OF MDM2, P300, P19ARF IN P53 UBIQUITINATION
-
批准号:6896793
-
项目类别:
-
资助金额:$15.74万
-
财政年份:2001
-
负责人:Steven R. Grossman
-
依托单位:
ROLE OF MDM2, P300, P19ARF IN P53 UBIQUITINATION
-
批准号:6514866
-
项目类别:
-
资助金额:$15.74万
-
财政年份:2001
-
负责人:Steven R. Grossman
-
依托单位:
ROLE OF MDM2, P300, P19ARF IN P53 UBIQUITINATION
-
批准号:6633921
-
项目类别:
-
资助金额:$15.74万
-
财政年份:2001
-
负责人:Steven R. Grossman
-
依托单位:
ROLE OF MDM2, P300, P19ARF IN P53 UBIQUITINATION
-
批准号:6728900
-
项目类别:
-
资助金额:$15.74万
-
财政年份:2001
-
负责人:Steven R. Grossman
-
依托单位:
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
-
批准号:30840003
-
项目类别:专项基金项目
-
资助金额:12.0万元
-
批准年份:2008
-
负责人:焦宇飞
-
依托单位: